218 related articles for article (PubMed ID: 28387573)
41. Stem cell-like breast cancer cells with acquired resistance to metformin are sensitive to inhibitors of NADH-dependent CtBP dimerization.
Banerjee A; Birts CN; Darley M; Parker R; Mirnezami AH; West J; Cutress RI; Beers SA; Rose-Zerilli MJJ; Blaydes JP
Carcinogenesis; 2019 Jul; 40(7):871-882. PubMed ID: 30668646
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells.
Gómez-Aleza C; Nguyen B; Yoldi G; Ciscar M; Barranco A; Hernández-Jiménez E; Maetens M; Salgado R; Zafeiroglou M; Pellegrini P; Venet D; Garaud S; Trinidad EM; Benítez S; Vuylsteke P; Polastro L; Wildiers H; Simon P; Lindeman G; Larsimont D; Van den Eynden G; Velghe C; Rothé F; Willard-Gallo K; Michiels S; Muñoz P; Walzer T; Planelles L; Penninger J; Azim HA; Loi S; Piccart M; Sotiriou C; González-Suárez E
Nat Commun; 2020 Dec; 11(1):6335. PubMed ID: 33303745
[TBL] [Abstract][Full Text] [Related]
43. Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models.
Zhu P; Davis M; Blackwelder AJ; Bachman N; Liu B; Edgerton S; Williams LL; Thor AD; Yang X
Cancer Prev Res (Phila); 2014 Feb; 7(2):199-210. PubMed ID: 24322659
[TBL] [Abstract][Full Text] [Related]
44. Clinical Impact of RANK Signalling in Ovarian Cancer.
Wieser V; Sprung S; Tsibulak I; Haybaeck J; Hackl H; Fiegl H; Marth C; Zeimet AG
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31181781
[TBL] [Abstract][Full Text] [Related]
45. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
46. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
47. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
48. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
Dougall WC
Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
[TBL] [Abstract][Full Text] [Related]
49. Denosumab Attenuates Glucolipotoxicity-Induced β-Cell Dysfunction and Apoptosis by Attenuating RANK/RANKL Signals.
Lin SC; Tsou SH; Kuo CY; Chen WL; Wu KW; Lin CL; Huang CN
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373436
[TBL] [Abstract][Full Text] [Related]
50. A Translational Study of the Neoplastic Cells of Giant Cell Tumor of Bone Following Neoadjuvant Denosumab.
Mak IW; Evaniew N; Popovic S; Tozer R; Ghert M
J Bone Joint Surg Am; 2014 Aug; 96(15):e127. PubMed ID: 25100780
[TBL] [Abstract][Full Text] [Related]
51. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
52. Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status.
Vazquez-Martin A; Oliveras-Ferraros C; Cufí S; Del Barco S; Martin-Castillo B; Menendez JA
Cell Cycle; 2010 Sep; 9(18):3807-14. PubMed ID: 20890129
[TBL] [Abstract][Full Text] [Related]
53. Denosumab: benefits of RANK ligand inhibition in cancer patients.
Lipton A; Jacobs I
Curr Opin Support Palliat Care; 2011 Sep; 5(3):258-64. PubMed ID: 21826000
[TBL] [Abstract][Full Text] [Related]
54. Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer.
Wahdan-Alaswad R; Harrell JC; Fan Z; Edgerton SM; Liu B; Thor AD
Cell Cycle; 2016; 15(8):1046-59. PubMed ID: 26919310
[TBL] [Abstract][Full Text] [Related]
55. [The mechanism of anti-RANKL antibody in the treatment of metabolic bone diseases including osteoporosis - possible applications of anti-RANKL antibody to the treatment of cancer patients].
Yasuda H
Nihon Yakurigaku Zasshi; 2019; 153(1):11-15. PubMed ID: 30643086
[TBL] [Abstract][Full Text] [Related]
56. Improved efficacy of mitochondrial disrupting agents upon inhibition of autophagy in a mouse model of BRCA1-deficient breast cancer.
Yeo SK; Paul R; Haas M; Wang C; Guan JL
Autophagy; 2018; 14(7):1214-1225. PubMed ID: 29938573
[TBL] [Abstract][Full Text] [Related]
57. Denosumab for the treatment of bone metastases in advanced breast cancer.
Casas A; Llombart A; Martín M
Breast; 2013 Oct; 22(5):585-92. PubMed ID: 23759273
[TBL] [Abstract][Full Text] [Related]
58. BRCA1 regulates the cancer stem cell fate of breast cancer cells in the context of hypoxia and histone deacetylase inhibitors.
Kim H; Lin Q; Yun Z
Sci Rep; 2019 Jul; 9(1):9702. PubMed ID: 31273285
[TBL] [Abstract][Full Text] [Related]
59. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation.
Chen G; Sircar K; Aprikian A; Potti A; Goltzman D; Rabbani SA
Cancer; 2006 Jul; 107(2):289-98. PubMed ID: 16752412
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment.
Bai YD; Yang FS; Xuan K; Bai YX; Wu BL
Med Hypotheses; 2008 Aug; 71(2):256-8. PubMed ID: 18445511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
